5 big analyst AI moves: Apple lifted to Buy, AI chip bets reassessed
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a pharmaceutical company with a market capitalization of $287.51 million and a "GOOD" financial health rating according to InvestingPro, announced that Andrew Dreyfus has notified the company of his resignation from its Board of Directors, effective November 1, 2025. The company stated that Mr. Dreyfus is stepping down due to his appointment as President and Chief Executive Officer of the National Institute for Health Care Management Foundation.
According to a press release statement included in the company’s filing with the U.S. Securities and Exchange Commission, the decision was not the result of any disagreement with Ironwood Pharmaceuticals or any matter related to its operations, policies, or practices.
The company expressed its appreciation for Mr. Dreyfus’s service and contributions during his tenure on the board.
Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, and its Class A common stock is listed on the Nasdaq Global Select Market under the ticker IRWD.
In other recent news, Ironwood Pharmaceuticals has made a significant change in its auditing team. The company announced that it has dismissed Ernst & Young LLP (EY) as its independent registered public accounting firm. This decision was taken by the Audit Committee after reviewing competitive proposals from various accounting firms. Subsequently, Ironwood Pharmaceuticals has appointed KPMG as its new auditor. The reports issued by EY for the years ending December 31, 2024, and December 31, 2023, were noted to have no adverse opinions or disclaimers. These reports were also not qualified or modified concerning uncertainty, audit scope, or accounting principles. The company communicated this change to EY on the same day the decision was made.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.